Congestion is central to the pathophysiology of heart failure (HF) and is the primary driver of symptoms in both outpatient and inpatient settings.

Despite the numerous improvements and breakthroughs developed in the field of interventional cardiology and pharmacotherapy in the past decades, patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention remain at high risk of cardiovascular events recurrence.

Until 20 years ago, when Alain Cribier revolutionized the treatment of valvular heart diseases, surgical aortic valve replacement and coronary artery bypass grafting represented the standard of care for patients with severe aortic stenosis and concomitant coronary artery disease (CAD) assessed by invasive coronary angiography.

The Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia (SURVIVE-VT) trial compares the efficacy and safety of catheter ablation versus antiarrhythmic drugs (AAD) as first-line therapy in patients with implantable cardioverter defibrillators (ICD) who present with symptomatic ventricular tachycardias (VT).

The ongoing COVID-19 pandemic has challenged health care systems worldwide and has brought to the forefront the limitations of providing high-quality health care under system stress.